HERON THERAPEUTICS, INC. /DE/ 8-K

What Happened
Heron Therapeutics, Inc. (HRTX) filed an 8‑K reporting the results of its 2026 Annual Meeting of Stockholders held June 11, 2026. Stockholders elected all seven director nominees (Craig Collard, Thomas Cusack, Sharmila Dissanaike, M.D., FACS, FCCM, Craig Johnson, Michael Kaseta, Adam Morgan, and Christian Waage) and ratified Withum Smith+Brown, PC as the company’s independent registered public accounting firm. Shareholders also approved, on a nonbinding basis, executive compensation (say‑on‑pay), approved an amendment to increase the 2007 Equity Incentive Plan by 16,560,000 shares, approved an amendment to increase the 1997 Employee Stock Purchase Plan by 10,000,000 shares, and ratified the Tax Benefits Preservation Plan.

Key Details

• Meeting logistics: record date April 14, 2026; 188,638,866 shares outstanding; 141,927,939 shares represented at the meeting (quorum).
• Directors: all seven nominees were elected; "For" votes for nominees ranged roughly from 85.3M to 88.5M shares, with 50,116,083 broker non‑votes.
• Equity authorizations: shareholders approved adding 16,560,000 shares to the 2007 Equity Incentive Plan (vote ~75.6M for / ~13.8M against).
• ESPP and other votes: shareholders approved adding 10,000,000 shares to the Employee Stock Purchase Plan (vote ~83.8M for / ~6.5M against); ratified Withum as auditor (~139.7M for); say‑on‑pay passed (~77.3M for / ~12.1M against); Tax Benefits Preservation Plan ratified (~88.2M for).

Why It Matters
These votes confirm board continuity and retain the current independent auditor, which supports governance stability. Approval of substantial share increases for the equity incentive plan (16.56M shares) and the ESPP (10M shares) authorizes the company to grant more stock‑based awards and employee purchase opportunities in the future — actions that can affect share count and potential dilution. The say‑on‑pay and Tax Benefits Preservation Plan were advisory/nonbinding items indicating shareholder support but not mandating operational changes. Investors should note the approved increases when assessing potential future dilution and executive compensation trends.